-
Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation Biomark. Res. (IF 4.866) Pub Date : 2021-01-19 Hooi Ching Lim; Shamit Soneji; Róbert Pálmason; Stig Lenhoff; Thomas Laurell; Stefan Scheding
Infection and graft-versus-host disease (GvHD) are the major causes for mortality and morbidity of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Plasma-derived extracellular vesicles (EVs) contain disease-related proteins, DNAs and RNAs, and have recently been suggested as potential biomarker candidates for transplantation complications. However, EV isolation from small plasma volumes
-
Prolonged elevation of serum neurofilament light after concussion in male Australian football players Biomark. Res. (IF 4.866) Pub Date : 2021-01-10 Stuart J. McDonald; William T. O’Brien; Georgia F. Symons; Zhibin Chen; Jesse Bain; Brendan P. Major; Daniel Costello; Glenn Yamakawa; Mujun Sun; Rhys D. Brady; Biswadev Mitra; Richelle Mychasiuk; Terence J. O’Brien; Sandy R. Shultz
Biomarkers that can objectively guide the diagnosis of sports-related concussion, and consequent return-to-play decisions, are urgently needed. In this study, we aimed to determine the temporal profile and diagnostic ability of serum levels of neurofilament light (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1), glial fibrillary acidic protein (GFAP), and tau in concussed male and female Australian
-
Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease Biomark. Res. (IF 4.866) Pub Date : 2021-01-09 Jung Eun Park; Do Sung Lim; Yeong Hee Cho; Kyu Yeong Choi; Jang Jae Lee; Byeong C. Kim; Kun Ho Lee; Jung Sup Lee
Alzheimer’s disease (AD) is the most common cause of dementia and most of AD patients suffer from vascular abnormalities and neuroinflammation. There is an urgent need to develop novel blood biomarkers capable of diagnosing Alzheimer’s disease (AD) at very early stage. This study was performed to find out new accurate plasma diagnostic biomarkers for AD by investigating a direct relationship between
-
Correction to: Length of hospitalization is associated with selected biomarkers (albumin and lymphocytes) and with co-morbidities: study on 4000 patients Biomark. Res. (IF 4.866) Pub Date : 2021-01-08 Antonio E. Pontiroli; Lara Loreggian; Marco P. L. Rovati; Elena De Patto; Laura Folini; Federico Raveglia; Matilde De Simone; Alessandro Baisi; Ugo Cioffi
An amendment to this paper has been published and can be accessed via the original article.
-
Cancer-associated adipocytes as immunomodulators in cancer Biomark. Res. (IF 4.866) Pub Date : 2021-01-07 Qi Wu; Bei Li; Juanjuan Li; Si Sun; Jingping Yuan; Shengrong Sun
Cancer-associated adipocytes (CAAs), as a main component of the tumor-adipose microenvironment (TAME), have various functions, including remodeling the extracellular matrix and interacting with tumor cells or infiltrated leukocytes through a variety of mutual signals. Here, we summarize the primary interplay among CAAs, the immune response and cancer with a focus on the mechanistic aspects of these
-
Metabolic reprogramming in macrophage responses Biomark. Res. (IF 4.866) Pub Date : 2021-01-06 Yang Liu; Ruyi Xu; Huiyao Gu; Enfan Zhang; Jianwei Qu; Wen Cao; Xi Huang; Haimeng Yan; Jingsong He; Zhen Cai
Macrophages are critical mediators of tissue homeostasis, with the function of tissue development and repair, but also in defense against pathogens. Tumor-associated macrophages (TAMs) are considered as the main component in the tumor microenvironment and play an important role in tumor initiation, growth, invasion, and metastasis. Recently, metabolic studies have revealeded specific metabolic pathways
-
Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania Biomark. Res. (IF 4.866) Pub Date : 2020-12-14 Luise Grunwald; Christina Grosse-Thie; Sina Sender; Gudrun Knuebel; Saskia Krohn; Catrin Roolf; Christian Junghanss; Larissa Henze; Hugo Murua Escobar
Myeloproliferative neoplasms are characterized by mutations in JAK2, MPL and CALR genes. Commonly in diagnostics and previous studies mainly sequencing and common PCR techniques under conventional detection limits are used. Splanchnic vein thromboses are rare, but often appear associated with myeloproliferative neoplasms and represent serious complications. Herein, blood from patients with abdominal
-
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse Biomark. Res. (IF 4.866) Pub Date : 2020-12-09 Sarah Cadot; Carine Valle; Marie Tosolini; Frederic Pont; Laetitia Largeaud; Camille Laurent; Jean Jacques Fournie; Loic Ysebaert; Anne Quillet-Mary
Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CLL evolution under ibrutinib therapy are well characterized for the leukemic cells but not for their microenvironment. Here, we addressed this question at the single cell level
-
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors Biomark. Res. (IF 4.866) Pub Date : 2020-12-09 Rui Zhang; Hao-Xiang Wu; Ming Xu; Xiaoyan Xie
Epigenetic factors play important roles in tumor immunology. Histone-lysine N-methyltransferase 2 (KMT2) family genes exert histone H3 methylation, but its role in immunotherapy remains unclear. Our study is the first to investigate the correlation between KMT2 gene mutations and the clinical benefit of immune checkpoint inhibitors (ICI) treatment. We firstly collected a primary ICI-treated cohort
-
Modulation of the TGF-β signaling pathway by long noncoding RNA in hepatocellular carcinoma Biomark. Res. (IF 4.866) Pub Date : 2020-12-01 Mengzhen Han; Zhibin Liao; Furong Liu; Xiaoping Chen; Bixiang Zhang
Hepatocellular carcinoma (HCC) is a type of liver cancer with poor prognosis. There have been demonstrated to exist many possible mechanisms in HCC tumorigenesis, and recent investigations have provided some promising therapy targets. However, further mechanisms remain to be researched to improve the therapeutic strategy and diagnosis of HCC. Transforming growth factor-β (TGF-β) is a pleiotropic cytokine
-
Recent updates on Sintilimab in solid tumor immunotherapy Biomark. Res. (IF 4.866) Pub Date : 2020-12-01 Xuhong Liu; Yong Yi
In recent years, there have been advancements in traditional patterns of tumor therapy with the adoption of immunotherapy. Its application with or without other combined regimens has attracted attention from clinicians. Sintilimab (Tyvyt®), a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction
-
A DNA methylation-based test for esophageal cancer detection Biomark. Res. (IF 4.866) Pub Date : 2020-11-25 Sofia Salta; Catarina Macedo-Silva; Vera Miranda-Gonçalves; Nair Lopes; Davide Gigliano; Rita Guimarães; Mónica Farinha; Olga Sousa; Rui Henrique; Carmen Jerónimo
Esophageal cancer (ECa) is the 7th most incident cancer and the 6th leading cause of cancer-related death. Most patients are diagnosed with locally advanced or metastatic disease, enduring poor survival. Biomarkers enabling early cancer detection may improve patient management, treatment effectiveness, and survival, are urgently needed. In this context, epigenetic-based biomarkers such as DNA methylation
-
Alternative Polyadenylation: a new frontier in post transcriptional regulation Biomark. Res. (IF 4.866) Pub Date : 2020-11-25 Fanggang Ren; Na Zhang; Lan Zhang; Eric Miller; Jeffrey J. Pu
Polyadenylation of pre-messenger RNA (pre-mRNA) specific sites and termination of their downstream transcriptions are signaled by unique sequence motif structures such as AAUAAA and its auxiliary elements. Alternative polyadenylation (APA) is an important post-transcriptional regulatory mechanism that processes RNA products depending on its 3′-untranslated region (3′-UTR) specific sequence signal.
-
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why? Biomark. Res. (IF 4.866) Pub Date : 2020-11-25 Huiwen Jiang; Yu Hu; Heng Mei
Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy shows good efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), it fails to improve long-term leukemia-free survival (LFS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CAR T-cell therapy has emerged as a promising strategy to prolong LFS. Nevertheless, which patients
-
Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML Biomark. Res. (IF 4.866) Pub Date : 2020-11-25 JingHan Wang; Xingnong Ye; Cuihua Fan; Jie Zhou; Shuna Luo; Jingxia Jin; Dan Chen; Yan Zheng; Cai Wu; Xiaoqiong Zhu; Jie Jin; Jian Huang
Recently, novel drugs like venetoclax plus 5-azacytidine (VA) were reported to have promising efficacy in refractory acute myeloid leukemia (AML). However, there are still some cases presented with novel drugs resistance, and its genetics composition and clinical phenotype are urging to study. We described a 58-year-old patient who was resistant to intensive chemotherapy. This refractory AML was presented
-
Biomarkers for cancer-associated fibroblasts Biomark. Res. (IF 4.866) Pub Date : 2020-11-11 Chencheng Han; Tongyan Liu; Rong Yin
Cancer-associated fibroblasts (CAFs) are the key component of tumor stromal. High heterogeneity of CAFs reflects in their origin, phenotype and function. Biological function which can be suggested by biomarkers of distinct CAF subgroups may be different, even opposite, just like water and fire. Identifying CAF subpopulations expressing different biomarkers and reconciling the relationship of the “water
-
The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications Biomark. Res. (IF 4.866) Pub Date : 2020-11-11 Natasha Mupeta Kaweme; Shu Zhou; Geoffrey Joseph Changwe; Fuling Zhou
Excessive generation of reactive oxygen species (ROS) in the presence of a defective antioxidant system can induce cellular damage and disrupt normal physiological functions. Several studies have revealed the unfavorable role of ROS in promoting the growth, proliferation, migration, and survival of leukemia cells. In this review study, we summarize the mechanisms of ROS production and its role in leukemogenesis
-
Recurrent SETD2 mutation in NPM1-mutated acute myeloid leukemia Biomark. Res. (IF 4.866) Pub Date : 2020-11-11 Jiewen Sun; Wenjuan Yu; Xiang Zhang
SETD2 is the only methyltransferase for H3K36me3, and our previous study has firstly demonstrated that it functioned as one tumor suppressor in hematopoiesis. Consistent with it, SETD2 mutation, which led to its loss of function, was identified in AML. However, the distribution and function of SETD2 mutation in AML remained largely unknown. Herein, we integrated SETD2-mutated AML cases from our center
-
N6-methyladenine modification in noncoding RNAs and its function in cancer Biomark. Res. (IF 4.866) Pub Date : 2020-11-10 Xinyu Yang; Xiang Hu; Jinting Liu; Ruiqing Wang; Chen Zhang; Fengjiao Han; Yuhong Chen; Daoxin Ma
Non-coding RNAs are the main component of the extensive transcription results of the mammalian genome. They are not transcribed into proteins but play critical roles in regulating multiple biological processes and affecting cancer progression. m6A modification is one of the most abundant internal RNA modification of mammalian cells, and it involves almost all aspects of RNA metabolism. Recent research
-
Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells Biomark. Res. (IF 4.866) Pub Date : 2020-11-10 Zhe Dai; Xu-yu Gu; Shou-yan Xiang; Dan-dan Gong; Chang-feng Man; Yu Fan
Malignant tumor is a largely harmful disease worldwide. The cure rate of malignant tumors increases with the continuous discovery of anti-tumor drugs and the optimisation of chemotherapy options. However, drug resistance of tumor cells remains a massive obstacle in the treatment of anti-tumor drugs. The heterogeneity of malignant tumors makes studying it further difficult for us. In recent years, using
-
Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function Biomark. Res. (IF 4.866) Pub Date : 2020-11-06 Prasant Kumar Jena; Lili Sheng; Michelle Nguyen; Jacopo Di Lucente; Ying Hu; Yongchun Li; Izumi Maezawa; Lee-Way Jin; Yu-Jui Yvonne Wan
Chronic consumption of high sugar and high fat diet associated with liver inflammation and cognitive decline. This paper tests a hypothesis that the development and resolution of diet-induced nonalcoholic fatty liver disease (NAFLD) has an impact on neuroplasticity and cognition. C57BL/6 wild-type mice were fed with either a healthy control diet (CD) or a fructose, palmitate, and cholesterol (FPC)-enriched
-
Targeting ferroptosis in breast cancer Biomark. Res. (IF 4.866) Pub Date : 2020-11-05 Zhaoqing Li; Lini Chen; Cong Chen; Yulu Zhou; Dengdi Hu; Jingjing Yang; Yongxia Chen; Wenying Zhuo; Misha Mao; Xun Zhang; Ling Xu; Linbo Wang; Jichun Zhou
Ferroptosis is a recently discovered distinct type of regulated cell death caused by the accumulation of lipid-based ROS. Metabolism and expression of specific genes affect the occurrence of ferroptosis, making it a promising therapeutic target to manage cancer. Here, we describe the current status of ferroptosis studies in breast cancer and trace the key regulators of ferroptosis back to previous
-
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo Biomark. Res. (IF 4.866) Pub Date : 2020-11-02 Qibin Liao; Yunyu Mao; Huan He; Xiangqing Ding; Xiaoyan Zhang; Jianqing Xu
On-target off-tumor toxicity impedes the clinical application of chimeric antigen receptor-modified T cells (CAR-T cells) in the treatment of solid tumors. Previous reports proved that the combinatorial antigen recognition strategy could improve the safety profile of CAR-T cells by targeting two different tumor-associated antigens (TAAs), one as a CAR-T targeted antigen and the other as a chimeric
-
Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing Biomark. Res. (IF 4.866) Pub Date : 2020-10-30 Qibin Liao; Huan He; Yunyu Mao; Xiangqing Ding; Xiaoyan Zhang; Jianqing Xu
Chimeric antigen receptor-modified T cells (CAR-T cells) have shown good effects in the treatment of hematologic cancers; however, they may cause on-target off-tumor toxicity because of minimal expression of tumor-associated antigens (TAAs) on normal tissues, particularly in the context of treating solid tumors. Hypoxia is a common hallmark of solid tumors because of the Warburg effect. To minimize
-
Assessment of serum macrophage migration inhibitory factor (MIF), adiponectin, and other adipokines as potential markers of proteinuria and renal dysfunction in lupus nephritis: a cross-sectional study Biomark. Res. (IF 4.866) Pub Date : 2020-10-28 Jorge Ivan Gamez-Nava; Valeria Diaz-Rizo; Edsaul Emilio Perez-Guerrero; Jose Francisco Muñoz-Valle; Ana Miriam Saldaña-Cruz; Nicte Selene Fajardo-Robledo; Heriberto Jacobo-Cuevas; Cesar Arturo Nava-Valdivia; Miriam Fabiola Alcaraz-Lopez; Xochitl Trujillo; Miguel Huerta; Ernesto German Cardona-Muñoz; Laura Gonzalez-Lopez
To date, the association of serum macrophage migration inhibitory factor (MIF) and serum adipokines with lupus nephritis is controversial. To assess the utility of serum MIF, leptin, adiponectin and resistin levels as markers of proteinuria and renal dysfunction in lupus nephritis. Cross-sectional study including 196 systemic lupus erythematosus (SLE) patients and 52 healthy controls (HCs). Disease
-
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia Biomark. Res. (IF 4.866) Pub Date : 2020-10-24 Carlos Cuesta-Mateos; Patricia Fuentes; Alexandra Schrader; Raquel Juárez-Sánchez; Javier Loscertales; Tamara Mateu-Albero; Lorena Vega-Piris; Marina Espartero-Santos; Ana Marcos-Jimenez; Blanca Andrea Sánchez-López; Yaiza Pérez-García; Dennis Jungherz; Sebastian Oberbeck; Linus Wahnschaffe; Anna Kreutzman; Emma I. Andersson; Satu Mustjoki; Edgar Faber; Ana Urzainqui; Manuel Fresno; Kostantino Stamatakis;
T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel therapies in T-PLL. As the chemokine receptor CCR7 is a molecule expressed in a wide range of malignancies
-
Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer Biomark. Res. (IF 4.866) Pub Date : 2020-10-23 Kiyoshi Misawa; Satoshi Yamada; Masato Mima; Takuya Nakagawa; Tomoya Kurokawa; Atsushi Imai; Daiki Mochizuki; Daichi Shinmura; Taiki Yamada; Junya Kita; Ryuji Ishikawa; Yuki Yamaguchi; Yuki Misawa; Takeharu Kanazawa; Hideya Kawasaki; Hiroyuki Mineta
New biomarkers are urgently needed to improve personalized treatment approaches for head and neck squamous cell carcinoma (HNSCC). Global DNA hypomethylation has wide-ranging functions in multistep carcinogenesis, and the hypomethylation of long interspersed nucleotide element-1 (LINE-1) is related to increased retrotransposon activity and induced genome instability. However, little information is
-
Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance Biomark. Res. (IF 4.866) Pub Date : 2020-10-15 Yue Zhang; Huizhu Qian; Jing He; Wen Gao
The tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs) are newly discovered noncoding RNAs in recent years. They are derived from specific cleavage of mature and pre-tRNAs and expressed in various cancers. They enhance cell proliferation and metastasis or inhibit cancer progression. Many studies have investigated their roles in the diagnosis, progression, metastasis, and prognosis of various cancers
-
Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer Biomark. Res. (IF 4.866) Pub Date : 2020-10-07 Nina Andersson; Johan Ohlsson; Sara Wahlin; Björn Nodin; Karolina Boman; Sebastian Lundgren; Karin Jirström
Screening across a multitude of normal and malignant tissues revealed an enhanced expression of lymphocyte antigen 6 superfamily member D (LY6D) in squamous epithelium and urothelium, as well as in malignancies derived therefrom. The aim of this study was to further delineate the protein expression of LY6D in urothelial bladder cancer, with particular attention to its relationship with clinicopathological
-
Novel insights on targeting ferroptosis in cancer therapy Biomark. Res. (IF 4.866) Pub Date : 2020-10-02 Sipeng Zuo; Jie Yu; Hui Pan; Linna Lu
Ferroptosis belongs to a novel form of regulated cell death. It is characterized by iron dependence, destruction of intracellular redox balance and non-apoptosis. And cellular structure and molecules level changes also occur abnormally during ferroptosis. It has been proved that ferroptosis exist widespreadly in many diseases, such as heart disease, brain damage or alzheimer disease. At the same time
-
Roles of IFN-γ in tumor progression and regression: a review Biomark. Res. (IF 4.866) Pub Date : 2020-09-29 Dragica Jorgovanovic; Mengjia Song; Liping Wang; Yi Zhang
Interferon-γ (IFN-γ) plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer. Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or
-
FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients Biomark. Res. (IF 4.866) Pub Date : 2020-09-25 Xiao-Jie Lu; Xiao-Jun Yang; Jing-Yu Sun; Xin Zhang; Zhao-Xin Yuan; Xiu-Hui Li
China is a highly endemic area of chronic hepatitis B (CHB). The accuracy of existed noninvasive biomarkers including TE, APRI and FIB-4 for staging fibrosis is not high enough in Chinese cohort. Using liver biopsy as a gold standard, a novel noninvasive indicator was developed using laboratory tests, ultrasound measurements and liver stiffness measurements with machine learning techniques to predict
-
A radiomics-based model on non-contrast CT for predicting cirrhosis: make the most of image data. Biomark. Res. (IF 4.866) Pub Date : 2020-09-17 Jin-Cheng Wang,Rao Fu,Xue-Wen Tao,Ying-Fan Mao,Fei Wang,Ze-Chuan Zhang,Wei-Wei Yu,Jun Chen,Jian He,Bei-Cheng Sun
To establish and validate a radiomics-based model for predicting liver cirrhosis in patients with hepatitis B virus (HBV) by using non-contrast computed tomography (CT). This retrospective study developed a radiomics-based model in a training cohort of 144 HBV-infected patients. Radiomic features were extracted from abdominal non-contrast CT scans. Features selection was performed with the least absolute
-
Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL. Biomark. Res. (IF 4.866) Pub Date : 2020-09-16 Wen-Hsin Liu,Paulina Mrozek-Gorska,Anna-Katharina Wirth,Tobias Herold,Larissa Schwarzkopf,Dagmar Pich,Kerstin Völse,M Camila Melo-Narváez,Michela Carlet,Wolfgang Hammerschmidt,Irmela Jeremias
Clinically relevant methods are not available that prioritize and validate potential therapeutic targets for individual tumors, from the vast amount of tumor descriptive expression data. We established inducible transgene expression in clinically relevant patient-derived xenograft (PDX) models in vivo to fill this gap. With this technique at hand, we analyzed the role of the transcription factor Krüppel-like
-
Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis Biomark. Res. (IF 4.866) Pub Date : 2020-09-15 Demetra H. Hufnagel; Andrew J. Wilson; Jamie Saxon; Timothy S. Blackwell; Jaclyn Watkins; Dineo Khabele; Marta A. Crispens; Fiona E. Yull; Alicia Beeghly-Fadiel
The canonical and non-canonical nuclear factor-kappaB (NF-κB) signaling pathways have key roles in cancer, but studies have previously evaluated only the association of canonical transcription factors and ovarian cancer survival. Although a number of in vitro and in vivo studies have demonstrated mechanisms by which non-canonical NF-κB signaling potentially contributes to ovarian cancer progression
-
Epigenetic based synthetic lethal strategies in human cancers Biomark. Res. (IF 4.866) Pub Date : 2020-09-15 Aiai Gao; Mingzhou Guo
Over the past decades, it is recognized that loss of DNA damage repair (DDR) pathways is an early and frequent event in tumorigenesis, occurring in 40-50% of many cancer types. The basis of synthetic lethality in cancer therapy is DDR deficient cancers dependent on backup DNA repair pathways. In cancer, the concept of synthetic lethality has been extended to pairs of genes, in which inactivation of
-
Advances in RNA cytosine-5 methylation: detection, regulatory mechanisms, biological functions and links to cancer. Biomark. Res. (IF 4.866) Pub Date : 2020-09-14 Chen Xue,Yalei Zhao,Lanjuan Li
As an important posttranscriptional modification of RNA, 5-methylcytosine (m5C) has attracted increasing interest recently, with accumulating evidence suggesting the involvement of RNA m5C modification in multiple cellular processes as well as tumorigenesis. Cooperatively, advances in m5C detection techniques have enabled transcriptome mapping of RNA methylation at single-nucleotide resolution, thus
-
Redox signaling and Alzheimer's disease: from pathomechanism insights to biomarker discovery and therapy strategy. Biomark. Res. (IF 4.866) Pub Date : 2020-09-11 Yuan-Yuan Chen,Min-Chang Wang,Yan-Ni Wang,He-He Hu,Qing-Quan Liu,Hai-Jing Liu,Ying-Yong Zhao
Aging and average life expectancy have been increasing at a rapid rate, while there is an exponential risk to suffer from brain-related frailties and neurodegenerative diseases as the population ages. Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide with a projected expectation to blossom into the major challenge in elders and the cases are forecasted to increase about
-
LncRNA SNHG16 as a potential biomarker and therapeutic target in human cancers. Biomark. Res. (IF 4.866) Pub Date : 2020-09-10 Yuhang Xiao,Ta Xiao,Wei Ou,Zhining Wu,Jie Wu,Jinming Tang,Bo Tian,Yong Zhou,Min Su,Wenxiang Wang
Long non-coding RNAs (lncRNAs) represent an important class of RNAs comprising more than 200 nucleotides, which are produced by RNA polymerase II. Although lacking an open reading framework and protein-encoding activity, lncRNAs can mediate endogenous gene expression by serving as chromatin remodeler, transcriptional or post-transcriptional modulator, and splicing regulator during gene modification
-
Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomark. Res. (IF 4.866) Pub Date : 2020-09-07 Xiaoya Yun,Ya Zhang,Xin Wang
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation
-
The role of estrogen receptor beta in breast cancer. Biomark. Res. (IF 4.866) Pub Date : 2020-09-07 Yujing Zhou,Xingdang Liu
Breast cancer, a malignant tumor originating from mammary epithelial tissue, is the most common cancer among women worldwide. Challenges facing the diagnosis and treatment of breast cancer necessitate the search for new mechanisms and drugs to improve outcomes. Estrogen receptor (ER) is considered to be important for determining the diagnosis and treatment strategy. The discovery of the second estrogen
-
The biological function and clinical significance of SF3B1 mutations in cancer. Biomark. Res. (IF 4.866) Pub Date : 2020-09-03 Zhixia Zhou,Qi Gong,Yin Wang,Mengkun Li,Lu Wang,Hongfei Ding,Peifeng Li
Spliceosome mutations have become the most interesting mutations detected in human cancer in recent years. The spliceosome, a large, dynamic multimegadalton small nuclear ribonucleoprotein composed of small nuclear RNAs associated with proteins, is responsible for removing introns from precursor mRNA (premRNA) and generating mature, spliced mRNAs. SF3B1 is the largest subunit of the spliceosome factor
-
A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark. Res. (IF 4.866) Pub Date : 2020-08-31 Celestin Danwang,Francky Teddy Endomba,Jan René Nkeck,Dominic Leandry Angong Wouna,Annie Robert,Jean Jacques Noubiap
Prognostic factors for the Coronavirus disease 2019 (COVID1–9) are not well established. This study aimed to summarize the available data on the association between the severity of COVID-19 and common hematological, inflammatory and biochemical parameters. EMBASE, MEDLINE, Web of sciences were searched to identify all published studies providing relevant data. Random-effects meta-analysis was used
-
Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report. Biomark. Res. (IF 4.866) Pub Date : 2020-08-31 Meng-Yun Li,Zhi-Hong Lin,Ming-Ming Hu,Li-Qing Kang,Xiao-Xia Wu,Qi-Wei Chen,Xin Kong,Jian Zhang,Hui-Ying Qiu,De-Pei Wu
Mixed phenotype acute leukemia (MPAL) is a rare leukemia and is regarded as a high-risk entity with a poor prognosis. Induction therapy of an acute lymphoblastic leukemia type or hybrid regimen and hematopoietic stem cell transplantation has been recommended for MPAL. However, the optimal therapies for relapsed or refractory MPAL remain unclear, especially for relapse after stem cell transplantation
-
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark. Res. (IF 4.866) Pub Date : 2020-08-26 Jin-Yu Sun,Dengke Zhang,Songquan Wu,Min Xu,Xiao Zhou,Xiao-Jie Lu,Jiansong Ji
PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clinical success. Despite the potentially cure-like survival benefit, only a minority of patients are estimated to experience a positive response to PD-1/PD-L1
-
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark. Res. (IF 4.866) Pub Date : 2020-08-26 Rilan Bai,Zheng Lv,Dongsheng Xu,Jiuwei Cui
Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era of anti-tumor therapy, with sustained responses and significant survival advantages observed in multiple tumors, most patients do not benefit. Therefore, more and more attention has been paid to the identification and development of predictive biomarkers for the response of ICIs, and more in-depth
-
A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression. Biomark. Res. (IF 4.866) Pub Date : 2020-08-26 Jialin Ma,Zheng Yan,Jiuyang Zhang,Wenping Zhou,Zhihua Yao,Haiying Wang,Junfeng Chu,Shuna Yao,Shuang Zhao,Peipei Zhang,Yuanlin Xu,Qingxin Xia,Jie Ma,Bing Wei,Shujun Yang,Kangdong Liu,Yongjun Guo,Yanyan Liu
Early progression after the first-line R-CHOP treatment leads to a very dismal outcome and necessitates alternative treatment for patients with diffuse large B-cell lymphoma (DLBCL). This study aimed to develop a genetic predictive model for early progression and evaluate its potential in advancing alternative treatment. Thirty-two hotspot driver genes were examined in 145 DLBCL patients and 5 DLBCL
-
Application of pharmacogenetics in oncology. Biomark. Res. (IF 4.866) Pub Date : 2020-08-17 Nelly N Miteva-Marcheva,Hristo Y Ivanov,Dimitar K Dimitrov,Vili K Stoyanova
The term “pharmacogenetics” is used to describe the study of variability in drug response due to heredity. It is associated with “gene – drug interactions”. Later on, the term “pharmacogenomics” has been introduced and it comprises all genes in the genome that can define drug response. The application of pharmacogenetics in oncology is of a great significance because of the narrow therapeutic index
-
Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. Biomark. Res. (IF 4.866) Pub Date : 2020-08-12 Dibyendu Dutta,Seah H Lim
Gut microbiota composition influences the balance between human health and disease. Increasing evidence suggests the involvement of microbial factors in regulating cancer development, progression, and therapeutic response. Distinct microbial species have been implicated in modulating gut environment and architecture that affects cancer therapy outcomes. While some microbial species offer enhanced cancer
-
Development of a highly sensitive method for detection of FLT3D835Y. Biomark. Res. (IF 4.866) Pub Date : 2020-08-12 Yao Guo,Honghua Sun,Dengyang Zhang,Yuming Zhao,Mingxia Shi,Ming Yang,Shu Xing,Xueqi Fu,Ting Bin,Bo Lu,Shunjie Wu,Xiaojun Xu,Xuesong Xu,Yun Chen,Zhizhuang Joe Zhao
Acute myeloid leukemia (AML) is a malignant hematological neoplasm of myeloid progenitor cells. Mutations of FLT3 in its tyrosine kinase domain (FLT3-TKD) are found in ~ 8% of patients with AML, with D835Y as the most common substitution. This mutation activates survival signals that drives the disease and is resistant to the first generation FLT3 inhibitors. Development of a highly sensitive method
-
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomark. Res. (IF 4.866) Pub Date : 2020-08-12 Era L Pogosova-Agadjanyan,Anna Moseley,Megan Othus,Frederick R Appelbaum,Thomas R Chauncey,I-Ming L Chen,Harry P Erba,John E Godwin,Isaac C Jenkins,Min Fang,Mike Huynh,Kenneth J Kopecky,Alan F List,Jasmine Naru,Jerald P Radich,Emily Stevens,Brooke E Willborg,Cheryl L Willman,Brent L Wood,Qing Zhang,Soheil Meshinchi,Derek L Stirewalt
The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal therapies. Despite the identification of many prognostic factors, relatively few have made their way into clinical practice. In order to assess and improve the performance of the European LeukemiaNet
-
Role of platelet biomarkers in inflammatory response. Biomark. Res. (IF 4.866) Pub Date : 2020-08-02 Yufei Chen,Haoxuan Zhong,Yikai Zhao,Xinping Luo,Wen Gao
Beyond hemostasis, thrombosis and wound healing, it is becoming increasingly clear that platelets play an integral role in inflammatory response and immune regulation. Platelets recognize pathogenic microorganisms and secrete various immunoregulatory cytokines and chemokines, thus facilitating a variety of immune effects and regulatory functions. In this review, we discuss recent advances in signaling
-
Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. Biomark. Res. (IF 4.866) Pub Date : 2020-07-17 Qiong Li,Wei Zhang,Jiali Li,Jingkang Xiong,Jia Liu,Ting Chen,Qin Wen,Yunjing Zeng,Li Gao,Lei Gao,Cheng Zhang,Peiyan Kong,Xiangui Peng,Yao Liu,Xi Zhang,Jun Rao
The early detection of tumors upon initial diagnosis or during routine surveillance is important for improving survival outcomes. Here, we investigated the feasibility and clinical significance of circulating tumor DNA (ctDNA) detection for Extranodal NK/T-cell lymphoma, nasal type (ENTKL). The plasma ctDNA assessment was based on blood specimens collected from 65 newly diagnosed patients with ENKTL
-
Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome. Biomark. Res. (IF 4.866) Pub Date : 2020-07-16 Kevin Courtet,Yec'han Laizet,Carlo Lucchesi,Alban Bessede,Antoine Italiano
Alterations of genes encoding subunits of the BAF/PBAF complexes are among the most frequent gene aberrations in human cancer. Such alterations have been shown to have an impact on tumor microenvironnement and on the capacity of tumors to respond to immune-checkpoint inhibitors (ICI). We analysed the clinical and genetic data from 43,728 patients accessed through cBioportal. The mutational frequencies
-
The emerging landscape of circular RNAs in immunity: breakthroughs and challenges. Biomark. Res. (IF 4.866) Pub Date : 2020-07-10 Zhouxiao Li,Ye Cheng,Fan Wu,Liangliang Wu,Hongyong Cao,Qian Wang,Weiwei Tang
Circular RNAs (circRNAs) are covalently linked RNAs that exhibit individual strand with a closed-loop framework compared with a conserving, steady and abundant linear counterpart. In recent years, as high-throughput sequencing advancement has been developing, functional circRNAs have been increasingly recognized, and more extensive analyses expounded their effect on different diseases. However, the
-
The emerging roles of N6-methyladenosine RNA methylation in human cancers. Biomark. Res. (IF 4.866) Pub Date : 2020-06-29 Huafei Shen,Yifen Lan,Yanchun Zhao,Yuanfei Shi,Jie Jin,Wanzhuo Xie
N6-methyladenosine (m6A) is the most abundant form of mRNA modification in eukaryotes. It affects various aspects of RNA metabolism, including nuclear export, translation, decay and alternative splicing. In addition, m6A also participates in a great number of human physiological processes, ranging from spermatogenesis modulation, response to heat shock, the control of T cell homeostasis to stem cell
-
Role of DNA repair defects in predicting immunotherapy response. Biomark. Res. (IF 4.866) Pub Date : 2020-06-29 Jing Zhang,David J H Shih,Shiaw-Yih Lin
Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defective mismatch repair has paved the way for investigating the role of other DDR defects in sensitizing cancer to ICB therapy. Despite great progress in understanding DDR pathways, the mechanisms
-
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomark. Res. (IF 4.866) Pub Date : 2020-06-25 Si-Yang Liu,Hao Sun,Jia-Ying Zhou,Guang-Ling Jie,Zhi Xie,Yang Shao,Xian Zhang,Jun-Yi Ye,Chun-Xiang Chen,Xu-Chao Zhang,Qing Zhou,Jin-Ji Yang,Yi-Long Wu
The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the KRAS G12C-specific inhibitor AMG510 showed promising results in the phase I clinical trial. However, the frequency, clinical characteristics, and prognostic significance of the KRAS G12C mutation in Chinese NSCLC patients are rarely reported
-
Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment. Biomark. Res. (IF 4.866) Pub Date : 2020-06-16 Shuiling Jin,Zhenzhen Yang,Xin Hao,Wenxue Tang,Wang Ma,Hong Zong
Myeloid-derived suppressor cells (MDSCs) are notable contributors to the immunosuppressive tumor microenvironment (TME) and are closely associated with tumor progression; in addition, MDSCs are present in most patients with cancer. However, the molecular mechanisms that regulate MDSCs in the etiopathogenesis of human tumor immunity remain unclear. The secreted alarmin high mobility group box 1 (HMGB1)